InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

November 16, 2020

Read More »

InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

November 13, 2020

Read More »

InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM”

November 12, 2020

Read More »

InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

November 5, 2020

Read More »

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

November 4, 2020

Read More »

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

September 24, 2020

Read More »

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

September 22, 2020

Read More »

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

September 8, 2020

Read More »

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

September 2, 2020

Read More »

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

July 7, 2020

Read More »

InMed Announces Completion of Share Consolidation

June 30, 2020

Read More »

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

June 24, 2020

Read More »

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

June 19, 2020

Read More »

InMed Releases CBN Preclinical Results in Glaucoma

May 27, 2020

Read More »

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

May 19, 2020

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

Read More »

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 12, 2020

Read More »

Notice of Telephone Scam Impersonating InMed

May 8, 2020

Read More »

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 8, 2020

Read More »